Navigation Links
PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
Date:4/30/2013

s486,845383,8121,371,3131,097,226Income from operations36,60628,21797,79563,263Other expense, net(773)(6,275)(3,370)(8,445)Income before income taxes35,83321,94294,42554,818Provision for income tax expense6,309(927)28,4949,448Effective tax rate17.6%-4.2%30.2%17.2%Net income$ 29,524$ 22,869$ 65,931$ 45,370Earnings per common share:Basic$0.51$0.38$1.12$0.76Diluted$0.50$0.38$1.10$0.75Shares used in computing earnings per common share:Basic58,02459,65258,94259,319Diluted59,07460,49460,00560,272Balance Sheet InformationPreliminaryMarch 31,March 31,June 30,201320122012Billed accounts receivable, net

$ 404,956$ 362,033$ 397,372Unbilled accounts receivable, net

246,071281,543251,845Deferred revenue

(395,438)(349,846)(359,714)Net receivables

$ 255,589$ 293,730$ 289,503Cash and marketable securities

$ 288,360$ 183,276$ 213,579Working capital

$ 410,292$ 364,072$ 359,590Total assets

$ 1,693,955$ 1,486,708$ 1,532,156Short-term borrowings

$ 10,002$ 5,004$ 5,003Long-term debt

$ 386,394$ 220,805$ 211,784Stockholders' equity

$ 551,924$ 595,889$ 609,675 

 PAREXEL International Corporation  Reconciliation of Non-GAAP MeasuresCertain Line Items(Unaudited)Three Months EndedThree Months Ended(in thousands, except per share data)March 31, 2013March 31, 2012GAAP MeasureAdjustmentsNon-GAAP MeasureGAAP MeasureAdjustmentsNon-GAAP MeasureSelling, general and administrative $
88,038$
(1,446)

(a)

$
86,592$
7,159$
7,159Restructuring (benefit) charge$
(732)$
732

(b)

$
-$
,807$
(1,807)

(e)

$
-Income from operations$
36,606$
714$
37,320$
28,217$
,807$
30,024Other expense, net$
(773)$
93

(c)

$
(680)$
(6,275)$
(6,275)Income before income taxes$
35,833$
807$
36,640$
21,942$
,807$
23,749Provisi
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
5. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
6. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
7. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
8. PAREXEL International to Present at Morningstar Conference
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call
10. UV Flu Technologies Expands Its International Footprint
11. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
(Date:7/23/2014)... , July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: ... that it is filing for two medical marijuana dispensary locations ... are in addition to the Clark County, Nevada ... special use permit, as previously announced.  GrowBLOX Sciences, ... be submitting two new applications for dispensaries in the ...
(Date:7/23/2014)... 2014 With the ability to record continuously ... more than 15 minutes, Fastec Imaging has brought the same ... speed imaging. “Finally, a high speed camera that can be ... our everyday lives.” proclaims Matt Kearney, VP of Sales for ... to demystify and simplify the traditionally complicated workflow of a ...
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... regenerative medicine transplant therapies are biological, but not ... trials may seem to treat them as if ... as well as unsanctioned studies that constitute “stem ... transplantation as an approach to developing new regenerative ...
Breaking Biology Technology:BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5
... in Physical ... Quality of Life, SAN FRANCISCO, Oct. 27 ... injections of golimumab (CNTO 148),50 mg and 100 mg, ... skin symptoms of active psoriatic arthritis,through six months with ...
... Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced ... that repeat administration with TRU-015 continues to ... arthritis,(RA) signs and symptoms based on American ... positive results following preliminary,analyses from a Phase ...
... MuriGen Therapeutics,today announced that its collaboration with ... drugs that target arthritis and other inflammatory diseases,has ... in February 2006 by MuriGen,Therapeutics and Zenyth Therapeutics ... therapeutic antibodies that inhibit the activity of the,cytokine ...
Cached Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL 2WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL 3
(Date:7/23/2014)... world by 2050, according to one of the scenarios ... may be advantageous to the physiology and the biochemical ... plants such as Stylosanthes capitata Vogel , a ... as Brazil., The conclusion is from a study carried ... the Ribeiro Preto Faculty of Philosophy, Sciences and Languages ...
(Date:7/23/2014)... SUP05 will play an increasingly important role in carbon ... minimum zones expand, according to research published this week ... Sciences . , University of British Columbia researchers plumbed ... Inlet, to chart how microbial community metabolism changes as ... very detailed picture of how SUP05 a bacterial ...
(Date:7/23/2014)... As of 2015, Springer will publish the International ... official journal of the Taiwan Fuzzy Systems Association (TFSA). ... global visibility in the area of fuzzy research., The ... to presenting high-quality papers that deal with the theory, ... gray systems and extension theory systems ranging from hardware ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Scientists are reporting the first-ever data to show that ... function of heart cells, and that loss of the protein ... Published Feb. 26 in the Journal of Biological ... online Feb. 19, the research was led by scientists at ...
... on Antarctica,s rich marine life are presented this week ... (AAAS). Marine Biologist Huw Griffiths from British Antarctic Survey ... the distribution and abundance of Antarctica,s vast marine biodiversity ... Griffiths presents results from the census which began ...
... BETHESDA, Md. (Feb. 16, 2010) A few minor ... endurance, according to a new study from Physiological Genomics ... more likely to have variations of the NRF2 gene than ... have the genetic variations compared to sprinters, although the difference ...
Cached Biology News:Scientists identify critical enzyme in healthy heart function 2Understanding global climate change through new breakthroughs in polar research 2Study finds variations in 1 gene may be associated with endurance running 2
... CUL-3 is a member of the family of human ... homologous to the S. cerevisiae cdc53 gene. Cullin-3 is ... It forms a tight complex with cyclin E and ... by protesomes. Cyclin E is an activator of cdk2, ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... nm; includes interface cable to S2000; can be ... or desktop boxes The LS-450 Blue ... produces either pulsed or continuous output at 470 ... measurements. The source is designed for use with ...
... for microRNA expression profiling ,miRCURY ... Locked Nucleic Acid (LNA) technology to provide ... short microRNA (miRNA) targets. miRCURY LNA Arrays ... RNA (no need for microRNA enrichment) labeled ...
Biology Products: